In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry
In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry
复制标题
DOI：
10.1016/j.humpath.2012.06.022
复制
发表时间：
2013-04-01
期刊：
影响因子：
3.3
通讯作者：
Kim, Woo Ho
中科院分区：
文献类型：
--
作者：
Kim, Min A.;Jung, Jung Eun;Kim, Woo Ho
抗HER2治疗的重要性使人们关注临床检测正确判定HER2扩增状态的能力。在本研究中，我们使用一种名为RNAscope的新型mRNA原位检测技术，对211例福尔马林固定、石蜡包埋的胃癌病例评估了HER2 mRNA的表达情况。此外，我们将结果与免疫组织化学、荧光原位杂交以及双色银染原位杂交等常规方法进行了比较。RNA原位杂交（原位杂交）显示，162例（76.8%）评分为0，5例（2.4%）评分为1，10例（4.7%）评分为2，13例（6.2%）评分为3，21例（10.0%）评分为4。发现HER2转录水平与pT分期、pN分期以及肿瘤复发显著相关。mRNA表达与蛋白过表达和基因扩增密切相关；23例有DNA扩增的病例中有20例在RNA原位杂交中评分为4（P <.001）。原位杂交有3例假阴性和1例假阳性结果。需要更多的研究来确定原位杂交方法是否能够识别出可能从抗HER2治疗中获益的其他患者，或者排除那些可能对抗HER2治疗耐药的患者。（C）2013爱思唯尔公司。保留所有权利。
The importance of anti-HER2 therapy has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. In the present study, we evaluated HER2 mRNA expression using a new mRNA in situ detection technique called RNAscope in 211 cases of formalin-fixed, paraffin-embedded gastric carcinoma. In addition, we compared the results with the conventional methods of immunohistochemistry, fluorescence in situ hybridization, and dual-color silver in situ hybridization. RNA in situ hybridization (in situ hybridization) showed that 162 cases (76.8%) were score 0, 5 cases (2.4%) were score 1, 10 cases (4.7%) were score 2, 13 cases (6.2%) were score 3, and 21 cases (10.0%) were score 4. HER2 transcription levels were found to be significantly related to pT class, pN class, and tumor recurrence. mRNA expression was well correlated with protein overexpression and gene amplification; 20 cases out of 23 with DNA amplification showed a score of 4 in RNA in situ hybridization (P < .001). Three cases showed false negative and one case showed false positive results by in situ hybridization. More studies are needed to determine whether the in situ hybridization method can identify additional patients that may benefit from anti-HER2 therapy or exclude those who may be resistant to anti-HER2 therapy. (C) 2013 Elsevier Inc. All rights reserved.